POLYPID LTD (PYPD)

IL0011326795 - Common Stock

4.5571  +0.07 (+1.62%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

POLYPID LTD

NASDAQ:PYPD (4/24/2024, 3:30:00 PM)

4.5571

+0.07 (+1.62%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap21.87M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PYPD Daily chart

Company Profile

PolyPid Ltd. operates as a phase 3 biopharma company. The firm focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Company Info

POLYPID LTD

18 Hasivim Street, P.O Box 7126

Petah Tikva 49537

P: 972747195700

CEO: Amir Weisberg

Employees: 65

Website: https://www.polypid.com

PYPD News

News Image10 hours ago - PolyPid Ltd.PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company...

News Image2 months ago - PolyPid Ltd.PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company...

News Image2 months ago - PolyPid Ltd.PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections ...

News Image2 months ago - PolyPid Ltd.PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up;...

News Image3 months ago - PolyPid Ltd.PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

News Image4 months ago - Seeking AlphaPolyPid looks to raise $16.2M through private placement (NASDAQ:PYPD)

PolyPid announces $16.2M private placement financing with investors purchasing 3.4M shares at $4.81/share and receiving warrants to buy additional shares.

PYPD Twits

Here you can normally see the latest stock twits on PYPD, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example